Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer

Cited by (1,000)

Items 801–900 of 1,000

1. Dramatic response to neoadjuvant savolitinib in marginally resectable lung adenocarcinoma with MET exon 14 skipping mutation: A case report and literature review
   Jiangfang Tian, Zhen Lin, Yueyun Chen, Yang Fu, Zhenyu Ding · 2022 · Frontiers in Oncology
2. Anatomic lung resection after immune checkpoint inhibitors for initially unresectable advanced-staged non-small cell lung cancer: a retrospective cohort analysis
   Harry Etienne, Ludovic Fournel, Pierre Mordant, Bertrand Richard De Latour, Karel Pfeuty, Gil Frey, Agathe Seguin‐Givelet, Alex Fourdrain, Christophe Lancelin, Pascal Berna et al. · 2023 · Journal of Thoracic Disease
3. Safety of adjuvant atezolizumab after pneumonectomy/bilobectomy in stage II-IIIA non–small cell lung cancer in the randomized phase III IMpower010 trial
   Jay M. Lee, Eric Vallières, Beiying Ding, Ann Johnson, Jan Bhagwakar, Sanam Rashidi, Qian (Cindy) Zhu, Barbara Jennifer Gitlitz, Benny Weksler, Kimberly E. Costas et al. · 2023 · Journal of Thoracic and Cardiovascular Surgery
4. Prognostic role of preoperative fluorine-18 fluorodeoxyglucose-positron emission tomography/computed tomography with an image-based harmonization technique: A multicenter retrospective study
   Akira Hamada, Kazuhiro Kitajima, Kenichi Suda, T. Koga, Junichi Soh, Hayato Kaida, Kimiteru Ito, Tetsuro Sekine, Kyoshiro Takegahara, Hiromitsu Daisaki et al. · 2023 · JTCVS Open
5. Adagrasib: a novel inhibitor for KRAS G12C -mutated non-small-cell lung cancer
   Matthew Z. Guo, Kristen Ashley Marrone, Alexander I. Spira, Samuel Rosner · 2023 · Future Oncology
6. Multi-Center Real-World Outcomes of Nivolumab Plus Ipilimumab and Chemotherapy in Patients with Metastatic Non-Small-Cell Lung Cancer
   Walid Shalata, Alexander Yakobson, Yulia Dudnik, Forat Swaid, Mohammad Sheikh‐Ahmad, Ashraf Abu Jama, Ahron Yehonatan Cohen, Abed Agbarya · 2023 · Biomedicines
7. Perioperative Nivolumab in Resectable Lung Cancer
   Simona Sobrero, Federico Vaisitti, Francesco Leo · 2024 · New England Journal of Medicine
8. Bis(benzonitrile) dichloroplatinum (II) interrupts PD-1/PD-L1 interaction by binding to PD-1
   Rui-na Wang, Qian Yu, Xiao-bo Wang, Di Zhu, Guolong Li, Zeng-xia Li, Wei Jiang, Wei Li, Yongjun Dang · 2023 · Acta Pharmacologica Sinica
9. Targeting Liver Metastases to Potentiate Immunotherapy in MS-Stable Colorectal Cancer—A Review of the Literature
   Oran Zlotnik, Lucyna Krzywoń, Jennifer Kalil, Jessica Bloom, Ikhtiyar Al Tubi, Anthoula Lazaris, Peter P. Metrakos · 2023 · Cancers
10. Salvage lung resection after immunotherapy is feasible and safe
    Attila Németh, Maureen Canavan, Peter L. Zhan, Brooks V. Udelsman, Sora Ely, Dennis A. Wigle, Linda W. Martin, Chi‐Fu Jeffrey Yang, Daniel J. Boffa, Andrew P. Dhanasopon · 2024 · JTCVS Open
11. Endocrine adverse events in patients with cancer receiving perioperative immune checkpoint blockade: a meta-analysis of randomized controlled trials
    Susu Zhou, Nobuyuki Horita, Theresa H. Shao, Matthew D. Harrington, Yu Fujiwara · 2024 · Therapeutic Advances in Medical Oncology
12. Contemporary Concise Review 2023: Advances in lung cancer and interventional pulmonology
    Tracy L. Leong, Daniel Steinfort · 2024 · Respirology
13. Theranostic Nanoplatform Based on Polydopamine-Coated Magnetic Mesoporous Silicon for Precise Cancer Triplex Nanotherapy and Multimodal Imaging
    Yuanyuan Gao, Yüjia Luo, Wenyu Chen, Xinrui Xue, Chujie Xiao, Kun Wei · 2024 · Analytical Chemistry
14. Five-year follow-up of neoadjuvant PD-1 inhibitor (sintilimab) in non-small cell lung cancer
    Bolun Zhou, Fan Zhang, Wei Guo, Shuhang Wang, Ning Li, Bin Qiu, Liang Zhao, Jian Li, Kang Shao, Qi Xue et al. · 2024 · Journal for ImmunoTherapy of Cancer
15. Heterogeneity in peripheral blood immune lymphocyte subsets predicts the response of immunotherapy or chemoradiotherapy in advanced lung cancer: an analysis across different pathological types, treatment modalities and age
    Chuanwang Miao, Yuanji Chen, Hao Zhang, Wei Zhao, Cunliang Wang, Zeliang Ma, Shan Zhu, Xudong Hu · 2024 · Frontiers in Immunology
16. Confronting synchronous multiple primary lung cancers: Navigating the intersection of challenges and opportunities
    Xue He, Zhihui Yang, Fang Wu, Qingchun Liang, Wenliang Liu, Fenglei Yu, Chen Chen · 2024 · Lung Cancer
17. Racial/ethnic differences in survival and treatment response with PD-1/PD-L1 inhibitors in resectable non-small cell lung cancer: a meta-analysis of randomized controlled trials
    Francisco Cézar Aquino de Moraes, Eric Pasqualotto, Anna Luíza Soares de Oliveira Rodrigues, Rommel Mário Rodríguez Burbano · 2024 · European Journal of Clinical Pharmacology
18. First in Human Evaluation of a Novel Thin Convex Probe Endobronchial Ultrasound System
    Nicholas J. Pastis, Vidhya Y. Aroumougame, Christopher R. Gilbert, Adam H. Fox, Nichole T. Tanner, Travis L. Ferguson, Gerard A. Silvestri · 2024 · Respiration
19. Perioperative immunotherapy plus chemotherapy versus chemotherapy alone for patients with resectable pulmonary lymphoepithelioma-like carcinoma
    Mengjie Lei, Xuanye Zhang, Lina Hu, Sha Fu, Meihua Xiao, Zhiqing Long, Honglin Zhu, Yixin Zhou, Shaodong Hong · 2024 · Lung Cancer
20. Prevalence of EGFR Mutations in Patients With Resected Stage I to III Nonsquamous Non–Small Cell Lung Cancer: Results of India Cohort
    Ullas Batra, Kumar Prabhash, Vanita Noronha, Ramakant Deshpande, Sachin Khurana, Gull Mohammad Bhat, Rajesh Mistry, Vivek Agarwala, Sajjan Rajpurohit, Bhavesh Pradip Poladia et al. · 2025 · JCO Global Oncology
21. Proposal of real-world solutions for the implementation of predictive biomarker testing in patients with operable non-small cell lung cancer
    Paul M Hofman, Petros Christopoulos, Nicky D’Haene, John R. Gosney, Nicola Normanno, Ed M. D. Schuuring, Ming‐Sound Tsao, Christine M. Quinn, Jayne Russell, Katherine E. Keating et al. · 2025 · Lung Cancer
22. Immune microenvironment features underlying the superior efficacy of neoadjuvant immunochemotherapy over chemotherapy in local advanced gastric cancer
    Ning Zhang, Chunyu Li, Zehua Zhao, Biying Jiang, Wentao Wang, Fujing Sun, Yong Zhang, Yanmei Zhu · 2025 · Frontiers in Immunology
23. Perioperative Chemo-Immunotherapy in Non-Oncogene-Addicted Resectable Non-Small Cell Lung Cancer (NSCLC): Italian Expert Panel Meeting
    Filippo de Marinis, Andrea Ardizzoni, Ilaria Attili, Laura Bonanno, Emilio Bria, Diego Luigi Cortinovis, Stefano Margaritora, Francesca Mazzoni, Edoardo Mercadante, Alessandro Morabito et al. · 2025 · Current Oncology
24. Molecular and immunological features associated with long-term benefits in metastatic NSCLC patients undergoing immune checkpoint blockade
    Pedro Rocha, Rafael Bach, Laura Masfarré, Sharia D. Hernandez, Nil Navarro-Gorro, Adrià Rossell, Xavier Villanueva, Mario Giner, Ignacio Sanchéz, Miguel Alejandro Galindo-Campos et al. · 2025 · OncoImmunology
25. Comparison of neoadjuvant chemoimmunotherapy with planned surgery and concurrent chemoradiation followed by immunotherapy for potentially resectable stage III non-small-cell lung cancer: a retrospective study
    Yana Qi, Xiaoyang Zhai, Qinhao Xu, Yuqin Jin, Yingfan Guo, Miaoqing Zhao, Huijuan Zhu, Hongbo Guo · 2025 · Cancer Immunology Immunotherapy
26. A Roadmap to Precision Immunotherapy for Early-Stage Non–Small Cell Lung Cancer
    Alessandra Vaccaro, Zahraa Rahal, Humam N. Kadara, Tina Cascone · 2025 · Cancer Discovery
27. Advantages of robotic-assisted thoracic surgery after neoadjuvant therapy in NSCLC: A propensity score–matched analysis
    Hong-Ji Li, Jia-Yan Ding, Qiang Nie, Hui-Zhao Hong, Zhen‐Bin Qiu, Rui Fu, Chao Zhang, Jia‐Tao Zhang, Ziyi Xu, Jie Yang et al. · 2025 · European Journal of Surgical Oncology
28. Efficacy and safety of anti-PD-1 versus anti-PD-L1 in perioperative immunotherapy: A comprehensive reanalysis of randomized controlled trials
    Chaoqi Zhang, Peng Wu, Dongyu Li, Junhan Zhou, Chuqi Lin, Xuanyu Gu, Dexin Shang, Ruijie Ma, Jingjing Liu, Guochao Zhang et al. · 2025 · Med
29. Comparison of robot-assisted and video-assisted thoracic sleeve lobectomy in non-small cell lung cancer: insights from a high-volume center
    Shiqi Hu, Xiaoping Zeng, Shiyue Wan, Suyu Wang, Qianxin Zhou, Ziyun Shen, Jing Zhang, Peng Zhang · 2025 · Journal of Thoracic Disease
30. Artificial intelligence–driven microsatellite instability profiling reveals distinctive genetic features in patients with lung cancer
    Quentin Dominique Thomas, Julie A. Vendrell, Lakhdar Khellaf, Sarah Cavaillon, Xavier Quantin, Jérôme Solassol, Simon Cabello‐Aguilar · 2025 · Cancer
31. Prognosis and relapse patterns in patients with non-small cell lung cancer with pathologic complete response after neoadjuvant immunochemotherapy
    Yifan Fang, Wanpu Yan, Ze-Rui Zhao, Long Jiang, Xiangyang Yu, Xin Yang, Zhentao Yu, Qingquan Luo, Hao Long, Ke‐Neng Chen · 2025 · Journal of Thoracic Disease
32. The role and clinical significance of tumor-draining lymph nodes in tumor progression and immunotherapy
    Qian Xu, Jiahui Chu, Qinqin Hu, Yanheng Sun, Fan Jiang, Song Li, Lian Liu · 2025 · Critical Reviews in Oncology/Hematology
33. Cancer-associated fibroblasts and metabolic reprogramming predict pathologic response to neoadjuvant PD-1 blockade in resected non-small cell lung cancer
    Jiaqi Zhao, Maolin Liu, Chongmei Zhu, Zhuolin Li, Zuhui Liu, Dilimulati Abulizi, Siqing Liu, Xin Wang, Haoxian Yang, Xue Hou · 2025 · Cellular Oncology
34. Non-invasive CT based multiregional radiomics for predicting pathologic complete response to preoperative neoadjuvant chemoimmunotherapy in non-small cell lung cancer
    Shuxuan Fan, Jiping Xie, Sunyi Zheng, Jing Wang, Bin Zhang, Zhanshuo Zhang, Shuo Wang, Yuechen Cui, Jiaxin Liu, Xinru Zheng et al. · 2025 · European Journal of Radiology
35. Induction chemoimmunotherapy may achieve non-inferior outcomes to consolidation immunotherapy in patients with unresectable stage III NSCLC: a real-world multicenter retrospective study
    Song Guan, Yu Wang, Qing Liu, Meng Yan, Kai Ren, Jun Wang, Nan Bi, Lujun Zhao · 2025 · Frontiers in Immunology
36. NK cell-derived extracellular vesicles enhance cytotoxicity and immune cell recruitment in non-small cell lung cancer
    J. Palade, E. Alsop, N. Tang, J. Antone, D. Paredes, T. Halder, R. Soldi, Taylor Bargenquast, Gary Schwartz, Jennifer P. Finholt et al. · 2025 · Frontiers in Immunology
37. Protocol for Chinese lung cancer evolution and microenvironment tracking under therapy study
    Wenxiang Wang, Yue He, Xiaoqiu Yuan, Lin Weng, Jing Bai, Xu Liu, Li Han, Junnan Xu, Shuai Wang, Shanshan Lu et al. · 2025 · Journal of Translational Internal Medicine
38. Neoadjuvant immunotherapy plus chemotherapy in locally advanced stage III NSCLC patients undergoing definitive chemo-radiotherapy---a real‑world multicenter retrospective study
    Guoyin Li, Chaoyuan Liu, Pan Xi, Liangxue Hou, Yaoxiong Xia, YunXiang Qi, Wenyan Pan, Wei Bai, Xiaoyan Li, Hao Zhou et al. · 2025 · Lung Cancer
39. Circulating tumor DNA dynamics predict pathological response and guide therapy personalization in the neoadjuvant setting
    Hani Moslem Ahmed, Ali Fawzi Al-Hussainy, Wael Waleed Mustafa, S. Renuka Jyothi, Priya Priyadarshini Nayak, J. Bethanney Janney, Gurjant Singh, Aashna Sinha, Hayder Naji Sameer, Rasim Mahdi Salih et al. · 2026 · Discover Oncology
40. Reconsidering adjuvant and perioperative immune-checkpoint inhibition: de-escalation, expansion and personalization
    Douglas Buckner Johnson, Amin H. Nassar, Ayesha Aijaz, Andrew David Knight, Mehmet Murat Zerey, Brian I. Rini, Abdul Rafeh Naqash, Ryan Joseph Sullivan · 2026 · Nature Reviews Clinical Oncology
41. Novel Inflammasome-Based Risk Score for Predicting Survival and Efficacy to Immunotherapy in Early-Stage Non-Small Cell Lung Cancer
    Chih‐Cheng Tsao, Hsin‐Hung Wu, Ying-Fu Wang, Po‐Chien Shen, Wen-Ting Wu, Huang-Yun Chen, Yang-Hong Dai · 2022 · Biomedicines
42. Programmed cell death protein 1 axis blockade in locally advanced squamous cell carcinoma of the head and neck: Neoadjuvant and adjuvant approaches
    Ioannis Athanasios Vathiotis, Jennifer Maria Johnson, Adam Luginbuhl, David M. Cognetti, Joseph Curry, Athanassios E. Argiris · 2022 · Cancer Treatment Reviews
43. STK11Inactivation Predicts Rapid Recurrence in Inoperable Early-Stage Non–Small-Cell Lung Cancer
    Rohan Reddy Katipally, Liam Flinn Spurr, Stanley I. Gutiontov, William Tyler Turchan, Philip P. Connell, Aditya Juloori, Renuka Malik, Michael Sargent Binkley, Alice L. Jiang, Sherin Juliet Rouhani et al. · 2023 · JCO Precision Oncology
44. Prognostic Role of Pathological Complete Response in Early Stage Epithelial Solid Tumors
    Giuseppe Saltalamacchia, Antônio Bernardo, Erica Quaquarini · 2023 · Cancer Control
45. B-Cell Infiltrate in the Tumor Microenvironment Is Associated With Improved Survival in Resected Lung Adenocarcinoma
    Ibiayi Dagogo‐Jack, Ivan Valiev, Nikita Kotlov, Anna Belozerova, Aleksandra Lopareva, Anna Butusova, Naira Samarina, Alexandra Boyko, Zhongmin Xiang, Monique Johnson et al. · 2023 · JTO Clinical and Research Reports
46. Pre-existing tumor host immunity characterization in resected non-small cell lung cancer
    Pedro Rocha, Maria Teresa Rodrigo‐Calvo, Laura Moliner, Sílvia Menéndez, Laura Masfarré, Nil Navarro, Raúl Del Rey-Vergara, Miguel Alejandro Galindo-Campos, Álvaro Taus, Mario Giner et al. · 2023 · Lung Cancer
47. Pathological complete response to long-course neoadjuvant alectinib in lung adenocarcinoma with EML4-ALK rearrangement: report of two cases and systematic review of case reports
    Liang Shi, Shuhong Gao, Tong Li, Qiyi Meng, Shijie Zhou, Daping Yu, Yujie Dong, Zhe Liu · 2023 · Frontiers in Oncology
48. A Th1-like CD4+ T-cell Cluster That Predicts Disease-free Survival in Early-stage Lung Cancer
    Akitoshi Yanagihara, Satoshi Yamasaki, Kosuke Hashimoto, Ryo Taguchi, Tetsuya Umesaki, Hisao Imai, Kyoichi Kaira, Hiroyuki Nitanda, Hirozo Sakaguchi, Hironori Ishida et al. · 2023 · Cancer Research Communications
49. PTPRD/PTPRT mutation correlates to treatment outcomes of immunotherapy and immune landscape in pan-cancers
    Gangjian Wang, Xin Ji, Haojie Wang, Xiaohuan Tang, Xiaofang Xing, Jiafu Ji · 2023 · Chinese Journal of Cancer Research
50. Salvage surgery for advanced non-small cell lung cancer following previous immunotherapy: a retrospective study
    Mitsunori Higuchi, Sho Inomata, Hikaru Yamaguchi, Takuro Saito, Hiroyuki Suzuki · 2023 · Journal of Cardiothoracic Surgery
51. Immune-active tumor-adjacent tissues are associated with favorable prognosis in stage I lung squamous cell carcinoma
    Lisha Ying, Chunliu Zhang, Alexandre Reuben, Yiping Tian, Jiaoyue Jin, Canming Wang, Jing Bai, Xinyuan Liu, Jianfei Fang, Tingting Feng et al. · 2023 · iScience
52. Real-world outcomes of immunotherapy-based neoadjuvant therapy in resectable non-small cell lung cancer
    Jie Shen, Linping Gu, Yuwen Qi, Yaxian Yao, Shun Lü, Zhiwei Chen · 2023 · Frontiers in Immunology
53. Surgery for stage IIB–IIIB small cell lung cancer
    Zhida Huang, Yue Liu, Suyu Wang, Kaixing Ai, Peng Zhang · 2023 · World Journal of Surgical Oncology
54. Multi-omics integrative modelling for stereotactic body radiotherapy in early-stage non-small cell lung cancer: clinical trial protocol of the MONDRIAN study
    Stefania Volpe, Mattia Zaffaroni, Gaia Piperno, Maria Giulia Vincini, Maria Alessia Zerella, Federico Mastroleo, Federica Cattani, Cristiana Iuliana Fodor, Federica Bellerba, Tiziana Bonaldi et al. · 2023 · BMC Cancer
55. Clinical effectiveness of robotic-assisted compared to open or video-assisted lobectomy in Germany: a real-world data analysis
    Martin Eichhorn, Eva Bernauer, André Rotärmel, Manuel Heurich, Hauke Winter · 2024 · Interdisciplinary CardioVascular and Thoracic Surgery
56. A Multicenter Retrospective Case-Control Study on Simple vs Extended Sleeve Lobectomies
    Alessio Campisi, Andrea Dell’Amore, Eleonora Faccioli, Wentao Fang, Tangbin Chen, Chunyu Ji, Piotr Gabryel, Magdalena Sielewicz, Cezary Piwkowski, Samina Park et al. · 2024 · The Annals of Thoracic Surgery
57. Minimally invasive surgery for clinical T4 non-small-cell lung cancer: national trends and outcomes
    Jorge Humberto Rodríguez-Quintero, Mostafa Elbahrawy, Anne Michelle Montal, Rajika Jindani, Marc Vimolratana, Mohamed Kamel, Brendon Matthew Stiles, Neel P. Chudgar · 2024 · European Journal of Cardio-Thoracic Surgery
58. Immunotherapy for non-small cell lung cancer
    Hiroshi Kagamu · 2024 · Respiratory Investigation
59. Association Between Sex and Efficacy of Immune Checkpoint Inhibitors: A Systematic Review and Meta Analysis
    Jianxiong Lai, Xiaohong Kuang, Yi Fu, Jian Li · 2024 · Immunotherapy
60. Multidisciplinary approach for locally advanced non-small cell lung cancer (NSCLC): 2023 expert consensus of the Spanish Lung Cancer Group GECP
    Aylen Vanessa Ospina, Sergio Bolufer Nadal, José Luis Campo-Cañaveral de la Cruz, J.L. González-Larriba, Ivan Macía Vidueira, B. Massuti Sureda, Ernest Nadal, Florentino Hernándo, Antonio Álvarez, E. del Barco et al. · 2024 · Clinical & Translational Oncology
61. Neoadjuvant chemoimmunotherapy confers survival advantage for patients undergoing sleeve lobectomy
    Tao Chen, Jialiang Wen, Yiming He, Yifan Zhong, Jiajun Deng, Qiankun Chen, Yunlang She, Lei Jiang, Dong Xie, Deping Zhao et al. · 2024 · European Journal of Cardio-Thoracic Surgery
62. Targeting sinonasal undifferentiated carcinoma with a combinatory immunotherapy approach
    Austin T.K. Hoke, Yoko Takahashi, Michelle R. Padget, Javier A. Gomez, Moran Amit, Jared K. Burks, Diana Bell, Tongxin Xie, Patrick Soon‐Shiong, James W. Hodge et al. · 2024 · Translational Oncology
63. Differences in the risk of immune-related pneumonitis between PD-1 and PD-L1 inhibitors: a meta-analysis according to the new mirror-principle and PRISMA guidelines
    Yuan Tian, Zongxiu Yin, Chi Zhang, Zhuoqi Li, Yuanyuan Wang, Kai Zhang, Feng Chen, Qi Dang · 2024 · Cancer Immunology Immunotherapy
64. Advances in clinical trials on perioperative immune checkpoint inhibitors for resectable non-small cell lung cancer: A comprehensive review
    Siyuan Cui, Na Wang, Yangyueying Liang, Yuan Guang Meng, Xinyi Shu, Fanming Kong · 2024 · International Immunopharmacology
65. Neoadjuvant therapy in early-stage non-small cell lung cancer: A real-world analysis
    Leyla Ay, Daniel Steiner, Hannah Fabikan, Oliver Illini, Dagmar Krenbek, Thomas Klikovits, Michal Benej, Klaus Kirchbacher, Stefan Watzka, Arschang Valipour et al. · 2024 · Lung Cancer
66. A comprehensive nomogram for assessing the prognosis of non-small cell lung cancer patients receiving immunotherapy: a prospective cohort study in China
    Hongmei Li, Yuliang Yuan, Qianjie Xu, Guangzhong Liang, Zuhai Hu, Xiaosheng Li, Wei Yan Zhang, Haike Lei · 2024 · Frontiers in Immunology
67. Comparative efficacy of immunotherapy-based treatment versus chemotherapy-only in patients with unresectable NSCLC with disease progression post chemoradiation and durvalumab
    Francesco Cortiula, Talia Shentzer Kutiel, Melinda Laine Hsu, Lizza E.L. Hendriks, Amin H. Nassar, Mor Tal Moskovitz, So Yeon Kim, Matthew M. Mirsky, Ritujith Jayakrishnan, Martina Bortolot et al. · 2025 · European Journal of Cancer
68. Neoadjuvant Concurrent Chemo–Immuno–Radiation Therapy Followed by Surgery and Adjuvant Immunotherapy for Resectable Stage III N2 NSCLC: Primary Results From the SQUAT Trial (WJOG 12119L)
    Akira Hamada, Junichi Soh, Akito Hata, Kiyoshi Nakamatsu, Mototsugu Shimokawa, Yasushi Yatabe, Jun Suzuki, Masahiro Tsuboi, Hidehito Horinouchi, Yuichi Sakairi et al. · 2025 · Journal of Thoracic Oncology
69. The treatment in patients with unresectable locally advanced non-small cell lung cancer: Explorations on hot issues
    Yimeng Wang, Yao Wang, Jinming Yu, Xiangjiao Meng · 2022 · Cancer Letters
70. Late‐onset acute type 1 diabetes mellitus 7 months after discontinuation of pembrolizumab against lung cancer
    Seiya Ichihara, Michihiro Kunishige, Naoki Kadota, Yoshio Okano, Hisanori Machida, Nobuo Hatakeyama, Keishi Naruse, Tsutomu Shinohara, Eiji Takeuchi · 2022 · Thoracic Cancer
71. Moving Immune Checkpoint Inhibitors to Early Non-Small Cell Lung Cancer: A Narrative Review
    Giuseppe Viscardi, Fabiana Vitiello, Alberto Servetto, Valerio Gristina, Elio Gregory Pizzutilo, Maria Anna Canciello, Paola Maria Medusa, Fabio Salomone, Gaetano Di Guida, Mariano Mollica et al. · 2022 · Cancers
72. Chemotherapy: A partnership with immunotherapy in n on‐small cell lung cancer
    Ana Sofia Mendes, Raquel Romão, Joana Febra, Sérgio Xavier Azevedo, Paula Fidalgo, António Araújo · 2022 · Thoracic Cancer
73. Copy number variations mediate major pathological response to induction chemo-immunotherapy in unresectable stage IIIA-IIIB lung cancer
    Liang Zeng, Yuling Zhou, Xiangyu Zhang, Qinqin Xu, Chunhua Zhou, Fanxu Zeng, Wenjuan Jiang, Zhan Wang, Li Deng, Haiyan Yang et al. · 2023 · Lung Cancer
74. Risk factors for cognitive impairment in radically treated stage III NSCLC: Secondary findings of the NVALT-11 study
    Haiyan Zeng, Lizza E.L. Hendriks, Willem J. A. Witlox, Harry J.M. Groen, Anne‐Marie C. Dingemans, John O. Praag, José S.A. Belderbos, Ruud M A Houben, Vincent van der Noort, Dirk De Ruysscher · 2023 · Radiotherapy and Oncology
75. Current Approaches to Neoadjuvant Immunotherapy in Resectable Non-small Cell Lung Cancer
    Jay Parekh, Kaushal Parikh, Joshua E. Reuss, Alex Friedlaender, Alfredo Addeo · 2023 · Current Oncology Reports
76. Monitoring with circulating tumor cells in the perioperative setting of patients with surgically treated stages I–IIIA NSCLC
    Yago Garitaonaindía, R. Aguado, Aránzazu García‐Grande, Mar Córdoba, M J Coronado Albi, José Luis Campo Cañaveral, Virginia Calvo, M. Blanco Clemente, Ruth Álvarez, Marta Peñas et al. · 2023 · Translational Lung Cancer Research
77. Genomic profiling and metastatic risk in early-stage non–small cell lung cancer
    Cameron N. Fick, Elizabeth G. Dunne, Manendra B. Lankadasari, Brooke Mastrogiacomo, Tetsuhiko Asao, Stijn Vanstraelen, Yuan Liu, Francisco Sánchez-Vega, David Randolph Jones · 2023 · JTCVS Open
78. Root Extract of Trichosanthes kirilowii Suppresses Metastatic Activity of EGFR TKI-Resistant Human Lung Cancer Cells by Inhibiting Src-Mediated EMT
    Hyun-Ji Park, Shin‐Hyung Park · 2023 · Nutrition and Cancer
79. Clinical application of liquid biopsy genomic profiling in NSCLC: Asian perspectives
    Molly Siu Ching Li, Kevin K. S. Mok, Landon Long Chan, Tony S.K. Mok · 2023 · The Journal of Liquid Biopsy
80. Advancing neoadjuvant therapies in resectable non-small cell lung cancer: implications for novel treatment strategies and biomarker discovery
    Hyein Jeon, Rajvi Gor, Angelica D’Aiello, Brendon Matthew Stiles, Peter Bela Illei, Balázs Halmos · 2024 · Pathology & Oncology Research
81. A retrospective comparison of induction chemoimmunotherapy versus chemotherapy followed by concurrent chemoradiotherapy and consolidation immunotherapy in stage III non-small cell lung cancer
    Jing Zhao, Miao Da, Jiaqi Zhou, Siyu Guo, Yang Tang, Fen Lan, Lixia Xia, Ting Zhang, Jian Huang · 2024 · Frontiers in Oncology
82. Real-World Clinical Outcomes of Neoadjuvant Platinum-Based Chemotherapy with Nivolumab in Non-Small Cell Lung Cancer
    Walid Shalata, Sameh Daher, Natali Maimon Rabinovitch, Sivan Shamai, Waleed Kian, Ilit Turgeman, Yulia Dudnik, Olga Kazareen, Yulia Rovitsky, Edmond Sabo et al. · 2024 · Journal of Clinical Medicine
83. Unraveling the relapse-associated landscape and individualized therapy in stage I lung adenocarcinoma based on immune and mitochondrial metabolism hallmarks via multi-omics analyses
    Tao Zhan, Luyao Wang, Zewei Li, Huijing Deng, Liu Huang · 2024 · Computers in Biology and Medicine
84. Novel Strategies for Lung Cancer Interventional Diagnostics
    Robert Smyth, Ehab S. Billatos · 2024 · Journal of Clinical Medicine
85. Navigating the landscape of neoadjuvant immunotherapy for NSCLC: progress and controversies
    Yuzhu Chen, Fei Qi, Chenhao Sun, Peng Jiang, Xiangyu Xue, Xiaomei Yang, Xiaomi Li, Xin He, Yishuo Wang, Tongmei Zhang · 2025 · Therapeutic Advances in Medical Oncology
86. Resection and Reconstruction for Lung and Airway Tumors Invading the Carina
    Camilla Vanni, Erino Angelo Rendina, Giulio Maurizi, Antonio D’Andrilli · 2025 · Cancers
87. Future perspectives on immunotherapy for hepatocellular carcinoma
    Landon Long Chan, Stephen Lam Chan · 2025 · Therapeutic Advances in Medical Oncology
88. Clinical practice guidelines for perioperative multimodality treatment of non-small cell lung cancer
    Wenjie Jiao, Liang Zhao, Jiandong Mei, Jia Zhong, Yongfeng Yu, Nan Bi, Lan Zhang, Lvhua Wang, Xiaolong Fu, Jie Wang et al. · 2025 · Chinese Medical Journal
89. Safety and necessity of omitting mediastinal lymph node dissection in cN0/N1 non-small cell lung cancer after neoadjuvant immunotherapy
    Yuheng Zhou, Wenyu Zhai, Weizhen Sun, Han Yong-ping, Zhichao Lin, Di‐Han Liu, Yan Zheng, Xiaojuan Luo, Ze-Rui Zhao, Shoucheng Feng et al. · 2025 · Frontiers in Immunology
90. Perioperative Therapy in Oncogene-Driven Non–Small Cell Lung Cancer: Current Strategies and Unanswered Questions
    Teja Voruganti, Rosalyn I. Marar, Benjamin Aaron Bleiberg, Edoardo Garbo, Biagio Ricciuti, Kaushal Parikh, Charu Aggarwal · 2025 · American Society of Clinical Oncology Educational Book
91. Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy for locally advanced rectal cancer: 3-year survival from a phase 2 study
    Zhenyu Lin, Peng Zhang, Ming Cai, Gang Li, Tao Liu, Kailin Cai, Jing Wang, Junli Liu, Hongli Liu, Weikang Zhang et al. · 2025 · BMC Medicine
92. Is adjuvant immunotherapy necessary after neoadjuvant chemoimmunotherapy in patients with resectable stage III NSCLC? A two-center real-world study
    Song Guan, Hui Wang, Zhaoxin Chen, Fengrui Guo, Guozhen Yi, Xingyu Du, Jingjing Yan, Cuimeng Tian · 2025 · Cancer Immunology Immunotherapy
93. Circulating Hsp70: a tumor biomarker for lymph node metastases and early relapse in thoracic cancer
    Dominik Lobinger, Nicholas Taylor, Verena Messner, Sophie Seier, Johannes Bodner, Erika S. Roberts, Ali Bashiri Dezfouli, Alan Graham Pockley, Seyer Safi, Gabriele Multhoff · 2025 · BMC Cancer
94. Current practice of pathologic response assessment following chemoimmunotherapy for non‐small cell lung cancer ( NSCLC ) in Germany: first real‐world data from the multicentre Re‐ GraDE study
    Felix Elsner, Christiane Kümpers, German Ott, Julia Döring, Katharina Schildknecht, Annette Fisseler‐Eckhoff, Maximilian von Laffert, Lea Baier, Luca Giulini, Dietmar Kraus et al. · 2025 · Histopathology
95. Attrition with adjuvant, neoadjuvant, and perioperative immunotherapy-based treatment protocols in patients with resectable non-small-cell lung cancer. A meta-analysis of prospective trials
    Francesco Guerrera, Filippo Tommaso Gallina, Eleonora Balzani, Francesca Ambrosi, Alessandro Di Federico, Eleonora Faccioli, Giorgio Facheris, Roberto Ferrara, Alessandra Ferro, Federica Filipello et al. · 2025 · Lung Cancer
96. Lung cancer tumor immune microenvironment: analyzing immune escape mechanisms and exploring emerging therapeutic targets
    Zhen Wang, Honglei Guo, Yanqi Song, Aidi Wang, Yuting Yan, Lin Ma, Baoshan Liu · 2025 · Frontiers in Immunology
97. Hepatectomy alters adjuvant anti–PD-1 action in a mouse model of HCC but does not compromise neoadjuvant efficacy
    Roqiya Bouguerra, Sofia El Hajji, Charles‐Henri Wassmer, Arnaud Bakaric, Florence Slits, Beat Moeckli, Laura Rubbia‐Brandt, Stéphanie Lacotte, Christian Toso · 2025 · Hepatology
98. A New Era, New Risks: The Cardio-Oncology Perspective on Immunotherapy in Non-Small Cell Lung Cancer
    Luigi Tarantini, Giuseppina Gallucci, Alessandro Inno, Andrea Camerini, Maria Laura Canale, Mario Larocca, Francesca Zanelli, Maria Pagano, Giulia Alberti, Patrizia Ciammella et al. · 2025 · Cancers
99. Progression and Metastasis of Lung Cancer: Clinical Features, Molecular Mechanisms, and Clinical Managements
    Yunkui Zhang, Meixi Chen, Xumeng Fang, Yu Han, Yingke Li · 2025 · MedComm
100. Neoadjuvant Nivolumab plus Carboplatin and Paclitaxel in Patients with Locally Advanced Resectable Squamous Cell Carcinoma of the Head and Neck: A Phase II, Single-Arm Trial
     Ralph Zinner, Eric V. Mastrolonardo, Jennifer Maria Johnson, Kathryn L. Nunes, Pablo Llerena, Zachary T. Elliott, Madalina Tuluc, Joseph Curry, Christopher Fundakowski, Andrew Yampolsky et al. · 2025 · Clinical Cancer Research